



YOU WORK IN NEVERLAND

NEVER ENOUGH TIME. NEVER A RISK-FREE MOMENT.
AND DEFINITELY NO ROOM FOR ERROR.

More than ever, the land of never requires LifeShield®—
Hospira's premier line of IV safety equipment.

Engineered specifically for contamination control
and heightened performance in IV drug delivery,
LifeShield® Effect-IV™ helps hospitals take on IV risks
with confidence.

LIFESHIELD
PREMIER IV SAFETY SYSTEM

IT'S TIME TO INVEST IN IV SAFETY. TALK TO YOUR HOSPIRA REPRESENTATIVE.



LIFESHIELD
EFFECT-IV

Hospira, Inc., 275 North Field Drive, Lake Forest, IL 60045 P09-2026 Printed in the USA.

CLAVE®

CHEMOCLAVE®

TKO™

EFFECT-IV™

SPIROS™

MICROCLAVE®

CLC2000®

BLUNT CANNULA

GENIE™

MORE THAN EVER

NEVERLAND

REQUIRES LIFESHIELD® EFFECT-IV™

IN NEVERLAND

≈250,000 catheter-related bloodstream infections (CRBSIs) occur annually¹

- CRBSIs burden ICUs with additional length of stay: 6.5 to 20 days²
- 12%–25% risk of mortality¹

Ending CRBSIs is a national priority

- Zero reimbursement by CMS with private insurers to follow^{3,4}
- NQF calls for the elimination of all preventable hospital-acquired infections by 2014⁵

IT'S TIME TO INVEST IN IV SAFETY.

LIFESHIELD EFFECT-IV MAKES IV RISKS MORE MANAGEABLE

- Effectively disinfects a luer-activated valve injection port⁶
- A physical barrier against external contamination and wear⁶
- Ensures up to 96 hours of continuous antimicrobial and antiseptic protection⁶
- Provides visual confirmation of compliance with infection control practices⁶



Sterile, non-DEHP, latex-free, single-use, threaded cap. Contains a sponge saturated with 70% isopropyl alcohol—a standard disinfectant solution. Unique cap shape fits needleless injection port or other access points. Provides proven antimicrobial and antiseptic action for critical contamination control.

PRODUCT	LIST NUMBER
LifeShield Effect-IV	12201-01

CALL 1-877-946-7747 FOR YOUR FREE EVALUATION.

LIFESHIELD®
EFFECT-IV™

References: 1. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. *MMWR*. 2002;51(RR10):1-26. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm>. August 9, 2002. Accessed April 6, 2009. 2. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential financial implications. *Chest*. 2003;124(1):275-284. 3. Centers for Medicare & Medicaid Services. CMS proposes additions to list of hospital-acquired conditions for fiscal year 2009. <http://www.cms.hhs.gov/apps/media/press/factsheet.asp?counter=3042&intNumPerPage=10&CheckDate=&checkKey=&srchType=1&numDays=34008&srchOpt=08&srchData=&KeywordType=All&chkNewsType=6&intPage=&showAll=&pYear=&year=&desc=false&cbOrder=date>. Accessed April 6, 2009. 4. Bivley A. Medical insurers focus on 'never events.' *The Kansas City Star*. July 17, 2008: Business, C1. 5. National Quality Forum. National priorities partnership: priority areas and corresponding goals (letter and draft proposal). July 3, 2008. http://www.qualityforum.org/about/NPP/assets/NPP_Goals_07_03_08.pdf. Accessed April 6, 2009. 6. Data on file. Hospira, Inc.